Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Br J Haematol. 2013 Jan 29;161(1):76–86. doi: 10.1111/bjh.12222

Figure 2. Survival for older Hodgkin lymphoma (HL) patients based on International Prognostic Score (IPS) and including competing risk analysis.

Figure 2

There were no significant differences in (A) failure-free survival and (B) overall survival according to IPS for older HL patients. The (C) cumulative incidence of death due to HL/progression and death due to HL treatment/toxicity (i.e., treatment-related mortality) vs death incidence rate due to all other causes. The associated cumulative incidence of death at 3 and 5 years for older HL patients was 23% and 30%, respectively vs 7% and 12%, respectively, for all other causes. The (D) cumulative incidence of death due to HL treatment/toxicity was plotted separately. The associated 3- and 5-year incidences of death was 16% and 21%, respectively, due to HL/progression, 7% and 9%, respectively, due to toxicity, and 7% and 12%, respectively, due to other causes.